Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1351) 1351
Publication (192) 192
Book Chapter (22) 22
Dissertation (12) 12
Book Review (11) 11
Conference Proceeding (4) 4
Government Document (2) 2
Journal / eJournal (2) 2
Magazine Article (2) 2
Trade Publication Article (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
btk (780) 780
humans (667) 667
index medicus (605) 605
animals (328) 328
ibrutinib (327) 327
x-linked agammaglobulinemia (269) 269
oncology (251) 251
protein-tyrosine kinases - metabolism (249) 249
hematology (246) 246
activation (244) 244
protein-tyrosine kinases - genetics (232) 232
mice (230) 230
chronic lymphocytic-leukemia (224) 224
brutons tyrosine kinase (220) 220
male (218) 218
bruton's tyrosine kinase (217) 217
immunology (210) 210
protein-tyrosine kinases - antagonists & inhibitors (197) 197
tyrosine (197) 197
targeting btk (193) 193
mutation (182) 182
biochemistry & molecular biology (181) 181
female (178) 178
signal transduction (157) 157
hemic and lymphatic diseases (139) 139
expression (130) 130
agammaglobulinemia - genetics (128) 128
leukemia, lymphocytic, chronic, b-cell - drug therapy (127) 127
protein kinase inhibitors - pharmacology (126) 126
phosphorylation (120) 120
cell biology (119) 119
lymphoma (109) 109
cancer (108) 108
leukemia (108) 108
article (107) 107
pci-32765 (107) 107
pyrimidines - therapeutic use (106) 106
pharmacology & pharmacy (100) 100
pyrazoles - therapeutic use (100) 100
pyrimidines - pharmacology (100) 100
btk inhibitor (99) 99
chronic lymphocytic leukemia (98) 98
lymphomas (97) 97
agammaglobulinaemia tyrosine kinase (93) 93
protein kinase inhibitors - therapeutic use (91) 91
adult (87) 87
chemistry, medicinal (86) 86
inhibitor (86) 86
receptor (85) 85
analysis (82) 82
cll (81) 81
gene (81) 81
protein-tyrosine kinases - chemistry (80) 80
pyrazoles - pharmacology (80) 80
rituximab (80) 80
aged (78) 78
b-cell receptor (78) 78
protein-tyrosine kinase (77) 77
agammaglobulinemia (76) 76
cell line, tumor (76) 76
antineoplastic agents - therapeutic use (75) 75
apoptosis (75) 75
xla (75) 75
b-lymphocytes - immunology (74) 74
kinases (74) 74
middle aged (74) 74
research (74) 74
bruton tyrosine kinase (73) 73
therapy (73) 73
immune system diseases (71) 71
tyrosine kinase (71) 71
mutations (67) 67
syk (67) 67
btk gene (66) 66
proteins (66) 66
b cells (64) 64
mantle cell lymphoma (64) 64
care and treatment (63) 63
antineoplastic agents - pharmacology (62) 62
open-label (61) 61
signal transduction - drug effects (61) 61
abridged index medicus (60) 60
b-lymphocytes - metabolism (59) 59
cells (59) 59
chemotherapy (59) 59
child (58) 58
immunodeficiency (58) 58
survival (58) 58
protein kinase inhibitors - chemistry (57) 57
b-cell (56) 56
genetic aspects (56) 56
btk inhibitors (55) 55
cell line (55) 55
leukemia, lymphocytic, chronic, b-cell - pathology (54) 54
phenols (54) 54
pyrimidines - adverse effects (53) 53
receptors, antigen, b-cell - metabolism (53) 53
gene expression (52) 52
identification (52) 52
lymphocytes b (52) 52
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1361) 1361
French (5) 5
German (5) 5
Chinese (3) 3
Czech (2) 2
Italian (2) 2
Japanese (2) 2
Polish (2) 2
Russian (2) 2
Korean (1) 1
Portuguese (1) 1
Serbian (1) 1
Spanish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Ibrutinib in Relapsed Chronic Lymphocytic Leukemia REPLY
by Byrd, JC and O'Brien, S and James, DF
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 09/2013, Volume 369, Issue 13, pp. 1278 - 1279
MEDICINE, GENERAL & INTERNAL | BTK
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text A negative-feedback function of pkcb in the formation and accumulation of signalingactive b cell receptor microclusters within b cell immunological synapse
by Liu, Ce and Zhao, Xing Wang and Xu, Li Ling and Yi, Jun Yang and Shaheen, Samina and Han, Weidong and Wang, Fei and Zheng, Wenjie and Xu, Chenqi and Liu, Wanli
Journal of Leukocyte Biology, ISSN 0741-5400, 05/2015, Volume 97, Issue 5, pp. 887 - 900
Btk | Activation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma (FL) who progressed on BTK inhibitors
by Jain, Preetesh and Kanagal-Shamanna, Rashmi and Lucas, F. Anthony San and Nastoupil, Loretta and Romaguera, Jorge and Fayad, Luis and Oki, Yasuhiro and Westin, Jason and Medeiros, L. Jeffrey and Wang, Michael and Fowler, Nathan
British journal of haematology, ISSN 0007-1048, 9/2018, Volume 182, Issue 5, pp. 718 - 723
ibrutinib | follicular lymphoma | BTK
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text BTKC481S-Mediated resistance to ibrutinib in chronic lymphocytic leukemia
by Woyach, Jennifer A and Ruppert, Amy S and Guinn, Daphne and Lehman, Amy and Blachly, James S and Lozanski, Arletta and Heerema, Nyla A and Zhao, Weiqiang and Coleman, Joshua and Jones, Daniel and Abruzzo, Lynne and Gordon, Amber and Mantel, Rose and Smith, Lisa L and McWhorter, Samantha and Davis, Melanie and Doong, Tzyy-Jye and Ny, Fan and Lucas, Margaret and Chase, Weihong and Jones, Jeffrey A and Flynn, Joseph M and Maddocks, Kami and Rogers, Kerry and Jaglowski, Samantha and Andritsos, Leslie A and Awan, Farrukh T and Blum, Kristie A and Grever, Michael R and Lozanski, Gerard and Johnson, Amy J and Byrd, John C
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 13, pp. 1437 - 1443
Purpose Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift in therapy, and... 
BTK | OFATUMUMAB | THERAPY | ONCOLOGY | MUTATION | ORIGINAL REPORTS | Chemotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen‐induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)
by Chen, Jun and Kinoshita, Taisei and Gururaja, Tarikere and Sukbuntherng, Juthamas and James, Danelle and Lu, Daniel and Whang, Jennifer and Versele, Matthias and Chang, Betty Y
European Journal of Haematology, ISSN 0902-4441, 11/2018, Volume 101, Issue 5, pp. 604 - 612
ObjectivesBruton's tyrosine kinase (BTK) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) are expressed by human platelets. These kinases... 
BTK | tyrosine kinase expressed in hepatocellular carcinoma (TEC) | platelet | aggregation | inhibitor | Bruton's tyrosine kinase | Bruton's tyrosine kinase (BTK) | BTK inhibitor | ACTIVATION | PHOSPHORYLATION | IBRUTINIB | RECEPTOR | TARGETING BTK | B-CELL MALIGNANCIES | CHRONIC LYMPHOCYTIC-LEUKEMIA | LYMPHOMA | MICE | HEMATOLOGY | GPVI | Tyrosine | Medicine, Experimental | Phenols | Medical research | Hepatoma | Collagen | Liver cancer | Glycoprotein VI | Hepatocellular carcinoma | Platelet aggregation | Protein-tyrosine kinase | Bleeding
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses
by McCarter, Stuart J and Vijayvargiya, Prakhar and Sidana, Surbhi and Nault, Ashley M and Lane, Colleen E and Lehman, Julia S and Wilson, John W and Parikh, Sameer A and Nowakowski, Grzegorz S and Al-Kali, Aref
Leukemia & Lymphoma, ISSN 1042-8194, 01/2019, Volume 60, Issue 2, pp. 559 - 561
PERICARDITIS | ONCOLOGY | TARGETING BTK | HEMATOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development
by Crawford, James J and Johnson, Adam R and Misner, Dinah L and Belmont, Lisa D and Castanedo, Georgette and Choy, Regina and Coraggio, Melis and Dong, Liming and Eigenbrot, Charles and Erickson, Rebecca and Ghilardi, Nico and Hau, Jonathan and Katewa, Arna and Kohli, Pawan Bir and Lee, Wendy and Lubach, Joseph W and McKenzie, Brent S and Ortwine, Daniel F and Schutt, Leah and Tay, Suzanne and Wei, Binqing and Reif, Karin and Liu, Lichuan and Wong, Harvey and Young, Wendy B
Journal of Medicinal Chemistry, ISSN 0022-2623, 03/2018, Volume 61, Issue 6, pp. 2227 - 2245
Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fc gamma... 
IRREVERSIBLE INHIBITORS | CHEMISTRY, MEDICINAL | BTK INHIBITOR | INFLAMMATORY DISEASES | B-CELL MALIGNANCIES | MURINE LUPUS | DRUG DESIGN | IBRUTINIB | CHRONIC LYMPHOCYTIC-LEUKEMIA | MEDIATED GLOMERULONEPHRITIS | TARGETING BTK
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
by Martin, Peter and Martin, Peter and Bartlett, Nancy L and Blum, Kristie A and Blum, Kristie A and Park, Steven and Park, Steven and Maddocks, Kami and Ruan, Jia and Ruan, Jia and Ridling, LeAnn and Dittus, Christopher and Dittus, Christopher and Chen, Zhengming and Chen, Zhengming and Huang, Xiangao and Huang, Xiangao and Inghirami, Giorgio and Inghirami, Giorgio and DiLiberto, Maurizio and DiLiberto, Maurizio and Chen-Kiang, Selina and Chen-Kiang, Selina and Leonard, John P and Leonard, John P
Blood, ISSN 0006-4971, 2019, Volume 133, Issue 11, pp. 1201 - 1204
Single-agent ibrutinib is active in patients with previously treated mantle cell lymphoma (MCL); however, nearly half of all patients experience treatment... 
BTK | MULTICENTER | INHIBITION | SINGLE-ARM | HEMATOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumorinfiltrating macrophages
by Ping, Lingyan and Ding, Ning and Shi, Yunfei and Feng, Lixia and Li, Jiao and Liu, Yalu and Lin, Yufu and Shi, Cunzhen and Wang, Xing and Pan, Zhengying and Song, Yuqin and Zhu, Jun
Oncotarget, 2017, Volume 8, Issue 24, pp. 39218 - 39229
Btk | Immunomodulatory effect | Macrophages | Ibrutinib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
by Byrd, John C and Smith, Stephen and Wagner-Johnston, Nina and Sharman, Jeff and Chen, Andy I and Advani, Ranjana and Augustson, Bradley and Marlton, Paula and Commerford, S. Renee and Okrah, Kwame and Liu, Lichuan and Murray, Elaine and Penuel, Elicia and Ward, Ashley F and Flinn, Ian W
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 16, pp. 13023 - 13035
GDC-0853 is a selective, reversible, and non-covalent inhibitor of Bruton's tyrosine kinase (BTK) that does not require interaction with the Cys481 residue for... 
BTK | CLL | GCD0853
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Three targets in 1 shot against ibrutinib resistance
by Chiron, D
BLOOD, ISSN 0006-4971, 02/2019, Volume 133, Issue 9, pp. 888 - 889
BTK | HEMATOLOGY | MANTLE | Life Sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton’s tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines
by Ge, Yang and Yang, Haijun and Wang, Changyuan and Meng, Qiang and Li, Lei and Li, Yanxia and Sun, Huijun and Zhen, Yuhong and Liu, Kexin and Ma, Xiaodong
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 01/2017, Volume 25, Issue 2, pp. 765 - 772
A family of phosphoryl-substituted diphenylpyrimidine derivatives (Pho-DPPYs) were synthesized and biologically evaluated as potent BTK inhibitors in this... 
BTK | Inhibitor | DPPY | Leukemia | Phosphoryl
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis
by Yao, X and Sun, XY and Jin, SY and Yang, L and Xu, HJ and Rao, Y
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 07/2019, Volume 62, Issue 14, pp. 6561 - 6574
A structure-hopping strategy was applied to discover a series of novel 4-aminoquinoline-3-carboxamide derivatives as potent, reversible BTK inhibitors.... 
BTK INHIBITORS | SELECTIVE-INHIBITION | IRREVERSIBLE INHIBITORS | RN486 | DESIGN | ACTIVATION | CHEMISTRY, MEDICINAL | B-CELL | IBRUTINIB | TARGETING BTK | DOSAGE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text SDF1 alpha-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLC gamma 1 and RhoA
by Nimmagadda, SC and Frey, S and Muller, P and Wolleschak, D and Weinert, S and Keller, U and Edelmann, B and Fischer, T
HAEMATOLOGICA, ISSN 0390-6078, 06/2019, Volume 104, Issue 7
MIGRATION | SURVIVAL | LEUKEMIC TRANSFORMATION | BTK | HEMATOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia
by Kiss, Richárd and Kiss, Richárd and Alpár, Donát and Alpár, Donát and Gángó, Ambrus and Gángó, Ambrus and Nagy, Noémi and Nagy, Noémi and Eyupoglu, Ediz and Eyupoglu, Ediz and Aczél, Dóra and Aczél, Dóra and Matolcsy, András and Matolcsy, András and Csomor, Judit and Csomor, Judit and Mátrai, Zoltán and Bödör, Csaba and Bödör, Csaba
Haematologica, ISSN 0390-6078, 01/2019, Volume 104, Issue 1, pp. e38 - e41
BTK | HEMATOLOGY | MUTATIONS | Online Only
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Development of BTK inhibitors for the treatment of B-cell malignancies
by Kim, Hyung-Ook
Archives of Pharmacal Research, ISSN 0253-6269, 2/2019, Volume 42, Issue 2, pp. 171 - 181
BTK is a key component of B-cell receptor signaling and functions as an important regulator of cell proliferation and survival in B-cell malignancies. The... 
Pharmacy | BTK inhibitors | Noncovalent BTK inhibitors | BTK | Pharmacology/Toxicology | Ibrutinib | B-cell malignancies | CHEMISTRY, MEDICINAL | PCI-32765 | ACALABRUTINIB ACP-196 | THERAPY | IBRUTINIB RESISTANCE | TYROSINE KINASE INHIBITOR | CHRONIC LYMPHOCYTIC-LEUKEMIA | LYMPHOMA | PHARMACOLOGY & PHARMACY | ONO/GS-4059 | MUTATIONS | NEXT-GENERATION | Care and treatment | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825
by Wang, Xin and Tan, Yuan and Huang, Zhenglan and Huang, Ningshu and Gao, Miao and Zhou, Fangzhu and Hu, Jing and Feng, Wenli
Oncology reports, 08/2019
Diffuse large B‑cell lymphoma (DLBCL), the most common type of non‑Hodgkin's lymphoma, is classified into germinal center and activated B cell (ABC) subtypes.... 
Journal Article
Details down arrow
18. Full Text Delineating the role of cooperativity in the design of potent PROTACs for BTK
by Zorba, Adelajda and Nguyen, Chuong and Xu, Yingrong and Starr, Jeremy and Borzilleri, Kris and Smith, James and Zhu, Hongyao and Farley, Kathleen A and Ding, WeiDong and Schiemer, James and Feng, Xidong and Chang, Jeanne S and Uccello, Daniel P and Young, Jennifer A and Garcia-Irrizary, Carmen N and Czabaniuk, Lara and Schuff, Brandon and Oliver, Robert and Montgomery, Justin and Hayward, Matthew M and Coe, Jotham and Chen, Jinshan and Niosi, Mark and Luthra, Suman and Shah, Jaymin C and El-Kattan, Ayman and Qiu, Xiayang and West, Graham M and Noe, Mark C and Shanmugasundaram, Veerabahu and Gilbert, Adam M and Brown, Matthew F and Calabrese, Matthew F
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 07/2018, Volume 115, Issue 31, pp. E7285 - E7292
Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that simultaneously bind to a target protein and an E3 ligase, thereby leading... 
BTK | Catalytic | PROTAC | Targeted protein degradation | Proteasome | proteasome | SELECTIVE DEGRADATION | MULTIDISCIPLINARY SCIENCES | IBRUTINIB | targeted protein degradation | E3 UBIQUITIN LIGASES | CEREBLON | TARGETING BTK | PROTEIN-DEGRADATION | STRUCTURAL BASIS | CHRONIC LYMPHOCYTIC-LEUKEMIA | GENOME-WIDE | catalytic | KNOCKDOWN | Polyubiquitin - metabolism | Thermodynamics | Ubiquitination | Animals | Protein-Tyrosine Kinases - metabolism | Proteolysis | Agammaglobulinaemia Tyrosine Kinase | Cells, Cultured | Ubiquitin-Protein Ligases - metabolism | Rats | Ligands | Physiological aspects | Observations | Phosphotransferases | Biological Sciences | Physical Sciences | PNAS Plus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Changes in clinical stage identify patients with CLL and different outcome within iwCLL partial response: RESONATE study
by Moreno, Carol and Delgado, Julio and Byrd, John C and Zvagelsky, William L and Suzuki, Samuel and Hsu, Emily and James, Danelle F and Montserrat, Emili
British Journal of Haematology, ISSN 0007-1048, 04/2019, Volume 185, Issue 1, pp. 148 - 150
ibrutinib | BTK | CLL | chronic lymphocytic leukaemia | inhibitor | Binet | iwCLL | BTK inhibitor | CHRONIC LYMPHOCYTIC-LEUKEMIA | HEMATOLOGY | Leukemia | Patient outcomes | Chronic lymphatic leukemia | Correspondence
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenstrom's Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutations Status
by Cea, Michele and Cagnetta, Antonia and Acharya, Chirag and Acharya, Prakrati and Tai, Yu-Tzu and Yang, Guang and Lovera, Davide and Soncini, Debora and Miglino, Maurizio and Fraternali-Orcioni, Giulio and Mastracci, Luca and Nencioni, Alessio and Montecucco, Fabrizio and Ballestrero, Alberto and Hideshima, Teru and Chauhan, Dharminder and Gobbi, Marco and Lemoli, Roberto M and Munshi, Nikhil and Treon, Steven P and Anderson, Kenneth C
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 12/2016, Volume 22, Issue 24, pp. 6099 - 6109
BTK | Waldenstrom's Macroglobulinemia | combination therapy | NAMPT
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.